Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

The lawsuits come amid several recent studies showing a link between vision complications and people taking drugs ...

Noom will start offering smaller doses of compounded Wegovy (NVO), the blockbuster weight-loss drug, as the digital health ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

On a weekday morning in Dublin, a group of patients walked into a weight-loss clinic hoping to shed pounds. What they didn’t expect was to also lose their taste for alcohol. A new study has found that ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

(Note: The Hers platform offers access to Wegovy, if prescribed, for people 18 and older, at 50 percent off the retail price.) It’s a powerful tool for weight loss, but it’s not a magic ...